DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dominant beta-thalassemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDominant beta-thalassemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dominant beta-thalassemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hemoglobin subunit beta (HBB) — HBB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1DXT · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Dominant beta-thalassemia is a very rare subgroup of beta-thalassemia caused by heterozygous mutations that act as dominant negatives, rather than the usual recessive inheritance. A 2024 report from Turkey describes one such case: an anaemic patient with dominant beta-thalassemia due to a heterozygous mutation in exon 3 of the HBB gene. A 2017 case of thalassemia intermedia resulted from a rare combination of the c.46delT (Codon15 -T) mutation of the beta globin gene together with HPFH 3. The 2013 review notes that most beta-thalassemia molecular lesions involve the structural beta gene directly, but some act through distal cis effects, and rare trans-acting mutations have also been identified.
No drug treatment is tested or proposed in any of these abstracts. The 2008 study from Iran evaluated drug dependence, not drug treatment: among 207 beta-thalassemic patients, 19 (9.2%) were drug dependent, with the most common motivation being enjoyment. The prevalence was similar to the general population of Fars province (10.2%) and Iran (12.5%). Statistically significant risk factors for drug dependence were male sex, single marital status, surgical history, and family history of drug addiction.
The 2013 review states that understanding the molecular basis of beta-thalassemia has provided a paradigm for human genetics, and the 2017 report suggests that close observation of genotype-phenotype correlation will provide insight for molecular therapy. However, no specific molecular therapy, repurposed drug, or clinical trial for dominant beta-thalassemia is described in these abstracts. What is missing is any clinical trial testing a drug for this specific subgroup, any patient stratification by dominant-negative mutation type, and the funding to move from molecular description to therapeutic testing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cold Spring Harbor Perspectives in Medicine · 2013 · 387 citations · open access
The Molecular Basis of -Thalassemia
AbstractThe β-thalassemias are characterized by a quantitative deficiency of β-globin chains underlaid by a striking heterogeneity of molecular defects. Although most of the molecular lesions involve the structural β gene directly, some down-regulate the gene through distal cis effects, and rare trans-acting mutations have also been identified. Most β-thalassemias are inherited in a Mendelian recessive fashion but there is a subgroup of β-thalassemia alleles that behave as dominant negatives. Unraveling the molecular basis of β-thalassemia has provided a paradigm for understanding of much of human genetics.
Clinical Case Reports · 2017 · 3 citations · open access
Thalassemia intermedia phenotype resulting from rare combination of c.46delT [Codon15 (‐T)] mutation of beta globin gene and <scp>HPFH</scp> 3
AbstractThe beta thalassemia intermedia phenotype has several genotypes. Hematological and molecular diagnostic approach and logical and sequential conduct of various investigations are necessary for the diagnosis of these disorders. Close observations of the genotype-phenotype correlation will provide a better insight for the development of molecular therapy.
Dominant Beta Thalassemia: A Very Rare Cause of Thalassemia in a Mediterranean Country
AbstractBeta thalassemia is one of the monogenic disorders characterized by decreased production of β-globin chains and various types of mutations have been reported to cause thalassemia phenotype. On the other hand, rare mutations also affect and diversify the disease spectrum. Herein, we present an anemic patient from Turkey diagnosed with dominant β thalassemia due to a heterozygous mutation in exon 3 of the HBB gene.
Evaluation of prevalence of drug dependence in beta‐thalassemic patients and its risk factors
AbstractObjective: Beta thalassemia is a hereditary disease of hemoglobin synthesis that causes mild to severe microcytic anemia and hemosiderosis in many organs that in severe cases results in organ failure. Many of the patients need blood transfusions. Drug dependence is a recurrent and chronic problem that has both physiological and behavioral aspects.Methods and materials: A total of 207 β thalassemic patients were randomly assigned out of 810 β thalassemic patients that referred to Shiraz Coolys Center in May–July 2005 in the south of Iran. We studied the prevalence of addiction in these patients and compared this with the normal population. We also evaluated the probable risk factors of drug dependence. There was no other study found worldwide at this time.Results: Of these 207 patients, 19 (9.2%) patients were drug dependent and their most common motivation was acquisition of enjoyment. Among the several risk factors that were studied, sex (male), marital status (single), surgical history and family drug addiction history were found to be statistically significant (0.01<p value <0.05).Discussion: Although the prevalence of addiction in thalassemic patients (9.2%) was nearly the same in the normal population of Fars province (10.2%) and Iran (12.5%), it still has a high prevalence and it should be considered as a psychical‐social problem. As this study was the first one done regarding this topic, we hope that in the future more studies will be conducted to help these patients to have a better lifestyle and improve life expectancy and quality of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
